CytoDyn Names Robert E. Hoffman CEO as Jacob Lalezari Takes Science Role
CytoDyn announced on October 19 that Robert E. Hoffman will become chief executive on October 20, 2026, succeeding Dr. Jacob Lalezari. Lalezari will remain with the company as Head of Research and Translational Sciences, focusing on potential solid-tumor applications for leronlimab. Hoffman will retain his principal accounting officer responsibilities as CytoDyn advances clinical, regulatory and partnering plans.
Why it matters
The leadership change places the company’s finance chief in the top executive role while retaining Lalezari for scientific work. CytoDyn said the transition is intended to support oncology development, regulatory objectives and potential partnerships.
Key facts
- 1CytoDyn’s board appointed Robert E. Hoffman chief executive effective October 20, 2026. stocktitan.net
- 2Jacob Lalezari, who had been CEO since November 2023, will become Head of Research and Translational Sciences. stocktitan.net
- 3Hoffman will continue serving as CytoDyn’s principal accounting officer. stocktitan.net
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.